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In a screening for new growth factors released by mela-
noma cells, we found that the p185-phosphorylating ca-
pacity of a medium conditioned by a melanoma cell
line was due to the secretion of heregulin, a ligand for
the human epidermal growth factor receptor (HER)
family of receptor tyrosine kinases. Expression of
heregulin, including a new isoform, and secretion
of functionally active protein was found in several cell
lines. Receptor activation by heregulin, either autocrine
or paracrine, resulted in a potent growth stimulation
of both melanocytes and melanoma cells. Heregulin
receptor HER3 and coreceptor HER2 were the main
receptors expressed by these cells. Nevertheless, none
of the cell lines in our panel overexpressed HER2 or
HER3. In contrast, loss of HER3 was found in two cell
lines, whereas one cell line showed loss of functional
HER2, both types of deregulations resulting in unre-
sponsiveness to heregulin. This implies the heregulin/
HER system as a possible important physiologic growth
regulatory system in melanocytes in which multiple
deregulations may occur during progression toward
melanoma, all resulting in, or indicating, growth
factor independence. Key words: heregulin-neuregulin-1/
autocrine-paracrine communication/receptor tyrosine kinases.
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G
rowth of melanocytes and their malignant counter-
parts is regulated by a variety of cytokines and other
polypeptides (LaŁ zaŁ r-MolnaŁ r et al, 2000; Payne and
Cornelius, 2002). Under physiologic conditions,
melanocytes depend for their survival on paracrine
stimulatory factors provided by the surrounding keratinocytes
(Meier et al, 1998). Transformed melanocytes have a decreased de-
pendence on paracrine stimulation, which facilitates their survival
outside their natural environment, the epidermis. Changes in sev-
eral growth factor systems contribute to this decreased depen-
dence. Whereas overexpression of receptor tyrosine kinases
(RTK) may lead to increased growth factor sensitivity and con-
stitutive signaling, loss of expression may result in insensitivity to
inhibitory factors or indicate growth factor independence (Easty
and Bennett, 2000). Also, the pro¢le of growth factors secreted
by melanoma cells is frequently altered, compared to melano-
cytes.Whereas de novo expression of some growth factors by mel-
anoma cells may stimulate proliferation of these cells in an
autocrine loop, these factors may act on the surrounding cells as
well, stimulating or inhibiting these cells in a paracrine way
(Halaban, 2000; LaŁ zaŁ r-MolnaŁ r et al, 2000; Ruiter et al, 2002).
The human epidermal growth factor receptor (HER) family
of RTK consists of four members, epidermal growth factor
receptor (EGFR)/erbB1/HER1, neu/erbB2/HER2, erbB3/HER3,
and erbB4/HER4 (Olayioye et al, 2000; Yarden and Sliwkowski,
2001). Although constitutive activation of these receptors, owing
to overexpression, frequently occurs in various types of cancers
(ReŁ villion et al, 1998), this does not seem to be common in mela-
noma (Natali et al, 1994; Korabiowska et al, 1996; Persons et al,
2000; Fink-Puches et al, 2001). Constitutive RTK signaling may
also be the result of truncation, mutation, association with other
cell-surface proteins, transactivation via other receptors, or the
presence of autocrine loops (Blume-Jensen and Hunter, 2001;
Gullick, 2001). The latter may result from the aberrant expression
of HER ligands.
Neuregulin-1 is the term for a family of proteins derived by
alternative splicing from a single gene, functioning as ligand for
HER3 and HER4 (Holmes et al, 1992; Yarden and Sliwkowski,
2001). At present, at least 24 splice variants have been identi¢ed
in di¡erent species, of which 10 were found in humans. Alterna-
tive splicing at the N-terminus results in three types of proteins:
heregulins (HRG, type I) (Holmes et al, 1992), glial growth factors
(type II) (Marchionni et al, 1993), and sensory- and motor-neu-
ron-derived factors (type III) (Ho et al, 1995). Further alternative
splicing of HRG at the EGF-like domain (a or b), the C-terminal
part of the EGF-like domain (1, 2, or 3) (Fig 1), and/or at the
intracellular tail (a, b, or c) gives rise to closely related proteins,
di¡ering in size and cellular localization and having distinct
receptor activation potentials and functions (Wen et al, 1994;
Pinkas-Kramarski et al, 1996; Meyer et al, 1997). Transmembrane
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HRG typically function as precursor molecules that are subject to
the action of metalloproteinases. This results in the release of the
extracellular domain that may subsequently bind to nearby re-
ceptors (autocrine/paracrine action) (Montero et al, 2000; Shira-
kabe et al, 2001). Necessary and su⁄cient for receptor binding is
the EGF-like domain; the roles of the various other domains have
not been fully elucidated yet. Some regulation may be exerted by
the cytoplasmic tail (Liu et al, 1998a, b; Han and Fischbach, 1999)
or by interaction of the N-terminal heparin-binding motif with
other molecules such as cell surface heparan sulfate proteoglycans
(Li and Loeb, 2001). A recently proposed model for ligand-
mediated HER activation proposes receptor conformational
changes as the driving force for receptor activation (Cho and Lea-
hy, 2002; Garrett et al, 2002; Ogiso et al, 2002). For HRG, this
would mean that binding of its EGF-like domain to HER3 or
HER4 leads to an altered receptor conformation, thus promoting
dimerization with another HER, preferentially HER2. Hetero- or
homodimerization of the receptors leads to trans- and autopho-
sphorylation, creating speci¢c docking sites for signal transduc-
tion molecules (Dankort et al, 2001; Hellyer et al, 2001) and
initiating further downstream signaling.When only HER2 and
HER3 are present, this model of HRG-induced receptor activa-
tion implies that HER3, which lacks catalytic activity (Guy et al,
1994; Sierke et al, 1997), can only become phosphorylated in trans
by heterodimerization with HER2 (Kim et al, 1998). Conversely,
HER2, for which no direct ligand has been identi¢ed yet, only
becomes activated after ligand binding to HER3.
Based on the initial observation that conditioned medium
(CM) from a melanoma cell line induced a strong phosphoryla-
tion of HERs in MCF-7 mammary cancer cells, we decided to
dissect the role of this putative ligand^receptor system in mela-
nocytes and a panel of melanoma cell lines. Here, in 4 of a panel
of 13 melanoma cell lines, we describe a number of deregulations
in the HRG/HER system. Production and release of functionally
active HRG in the medium were found in three cell lines and
resulted in an autocrine loop in one case. Whereas exogenous
HRG-stimulated growth of the majority of melanoma cell lines
and melanocytes, three cell lines did not respond to HRG, owing
to the absence of HER3 or owing to a functionally incompetent
HER2.
MATERIALS ANDMETHODS
Cell lines The cell lines were obtained as follows: 530 and BLM
melanoma cell lines from L. Van Kempen (University of Nijmegen, the
Netherlands); A375 melanoma cell line from J. Hilkens (NKI, the
Netherlands); Bowes melanoma from G. Opdenakker (Rega Institute,
Belgium); DX3 and DX3azaLT5.1 melanoma cell lines from J. Ormerod
(Imperial Cancer Research Fund, UK); FM3/D, FM3/p, FM45, and FM87
melanoma cell lines from J. Zeuthen (Danish Cancer Society, Denmark);
HMB2, MeWo, and MJM melanoma cell lines from D. Rutherford
(Rayne Institute, St Thomas Hospital, UK); MCF-7/6 mammary carci-
noma cell line (further called MCF-7) from H. Rochefort (University
of Montpellier, France); COLO-16 squamous skin carcinoma cell line and
SK-BR-3 mammary carcinoma cell line from C. De Potter (Ghent Univer-
sity Hospital, Belgium); and MDA-MB-231 breast cancer cell line from
American Type Culture Collection (Manassas, VA). Cell lines were
routinely maintained in the following media (Gibco BRL, Belgium):
RPMI 1640 (FM and COLO-16 cell lines), L15 (MDA-MB-231), 50% Dul-
becco’s modi¢ed Eagle’s medium/50% Ham’s F12 (MCF-7), or Dulbecco’s
modi¢ed Eagle’s medium (all other cell lines). All media for rou-
tine culture contained 10% heat-inactivated fetal bovine serum (Greiner
Bio-One, Belgium), 100 IU per mL penicillin, 100 mg per mL strepto-
mycin, and 2.5 mg per mL amphotericin B. Epidermal melanocyte primary
cultures were obtained from neonatal foreskins and established in M199
medium (Gibco BRL), supplemented with 2% fetal bovine serum, 10^9 M
cholera toxin, 10 ng per mL basic ¢broblast growth factor (bFGF), 10 mg
per mL insulin, 1.4 mM hydrocortisone, and 10 mg per mL transferrin (all
from Sigma, Belgium). Postprimary cultures were maintained in low-
calcium (0.03 mM) M199 medium, supplemented with the same factors
and 10% fetal bovine serum. The melanocytic origin of all melanoma cell
lines was checked by immunocytochemistry using two antibodies against
melanoma-speci¢c proteins, HMB45 (Enzo Diagnostics, Farmingdale,
NY) and NKI/C3 (Biogenex, San Ramon, CA). All melanoma cell lines
were positive for at least one of these markers (data not shown). Because
most of the experiments were carried out with Bowes melanoma cells,
which were only positive for NKI/C3, additional electron microscopy was
performed to con¢rm the presence of premelanosome-like structures in
this nonpigmented cell line (data not shown).
Antibodies and reagents Primary antibodies used were: rabbit
polyclonal anti-HER1, -2, -3, and -4 and anti-HRG precursor antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal
antitubulin (Sigma), mouse antiphospho-mitogen-activated protein kinase
(MAPK; Westburg, the Netherlands), and antiphosphotyrosine antibody
RC20 conjugated to horseradish peroxidase (Transduction Laboratories,
Lexington, KY). Goat anti-HRG-a and recombinant HRG-b1, consisting
of the EGF-like domain of HRG (rHRG-b1, used at 10 ng/mL unless
indicated otherwise), was purchased from R & D Systems (Abingdon,
UK). Full-length recombinant HRG-b1 was obtained from Laboratory
Vision (Fremont, CA), whereas heparin, PD168393 (used at 2 mM, unless
indicated otherwise), and PD98059 were from Calbiochem (Darmstadt,
Germany).
Preparation of CM Subcon£uent monolayers were washed three times
with phosphate-bu¡ered saline (PBS), incubated for 24 h with serum-free
medium, and washed again three times with PBS, followed by a 48-h
incubation with serum-free medium. The latter medium was cleared from
cells by 5 min centrifugation at 250 g. The resulting supernatant was
centrifuged for an additional 20 min at 2000 g to remove cell debris,
¢ltered through a 0.2-mm ¢lter, and stored at ^201C until use. To isolate
the heparin-binding fraction from the CM, the latter was depleted from
heparin-binding factors by triple precipitations with heparin beads (Bio-
Rad, Hercules, CA). Elution of the heparin-binding fraction was done
with 1 M NaCl, followed by desalting and dilution in fresh serum-free
medium.
Figure1. Neuregulin-1 splicing variation in the EGF-like domain.
The scheme depicts the genomic organization of the exons encoding
the region surrounding the variable part of the EGF-like domain of the
NRG-1 gene. The locations of the sequences that are complementary to
the primers used for RT-PCR are indicated with S and AS for the sense
and antisense primers, respectively. The table indicates all possible splicing
variants within this domain with their expected ampli¢cation product
lengths in base pairs (bp), when using the indicated primer pair. NA, not
ampli¢ed; EGFc, sequence common in the EGF-like domain of all HRG;
hatched, coding sequence for the HRG transmembrane domain; asterisk, lo-
cation of the stop codon in case of the (a)^(b) combination; ?, putative
isoform not yet characterized.
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Western blotting and (immuno)precipitation All lysates were
made of cells of approximately 90% con£uence. For phosphorylation
experiments, cells were washed three times with PBS, serum-starved
overnight, washed again three times with PBS, and treated with serum-
free medium for the indicated times. Before making all lysates, the cells
were washed three times with PBS. Cells were lyzed with PBS containing
1% Triton X-100, 1% Nonidet P-40 (Sigma), and the following protease
inhibitors: aprotinin (10 mg/mL), leupeptin (10 mg/mL) (ICN Biomedicals,
Costa Mesa, CA), phenylmethylsulfonyl £uoride (1.72 mM), NaF (100 mM),
NaVO3 (500 mM), and Na4P2O7 (500 mg/mL) (Sigma). After clearing the
lysates, protein concentration was determined using Rc Dc protein assay
(Bio-Rad), and samples were prepared such that equal amounts of protein
were to be loaded. For immunoprecipitation, equal amounts of protein
were ¢rst incubated with protein A^Sepharose (Amersham Pharmacia
Biotech, UK) for 30 min. After discarding the beads, the supernatant was
incubated with primary antibody for 3 h at 41C, followed by incubation
with the added protein A^Sepharose beads for 1 h. For heparin and
streptavidin precipitations, cell lysates were incubated with heparin
beads (Bio-Rad) or streptavidin beads (Sigma). Sample bu¡er (Laemmli)
with 5% 2-mercaptoethanol and 0.012% bromophenol blue was added,
followed by boiling for 5 min and separation of proteins by gel
electrophoresis on a 8 or 12% polyacrylamide precast gel (Invitrogen, San
Diego, CA) and transfer onto a nitrocellulose membrane (Amersham
Pharmacia Biotech). Quenching and immunostaining of the blots were
done in 5% nonfat dry milk in PBS containing 0.5% Tween 20, except
for RC-20 and antiphospho-MAPK antibodies, where 4% bovine serum
albumin in PBS containing 0.2% Tween 20 was used instead. The
membranes were quenched for 1 h, incubated with primary antibody for 1
h, washed four times for 10 min, incubated with horseradish peroxidase-
conjugated secondary antibody for 45 min, and washed six times for 10
min. Detection was done using enhanced chemiluminescence reagent
(Amersham Pharmacia Biotech) as a substrate. To control for equal
loading of total lysates, immunostaining with antitubulin antibody was
performed routinely (not shown). Quanti¢cation of bands was done using
Quantity-One software (Bio-Rad).
RT-PCR, cloning, and sequencing Total RNA was extracted from
approximately 5106 cells using the Qiagen RNeasy kit (Qiagen,
Chatsworth, CA). One microgram of total RNA was reverse transcribed
with oligo(dT) primers using the Qiagen RT kit (Qiagen) according to
the manufacturer’s instructions. HRG cDNA encoding all transmembrane
isoforms was ampli¢ed using the sense primer 50 -CTGTGTGAATGGAG-
GGGAGTGC-30 (complementary to a sequence encoding a conserved
part of the EGF-like domain) and the antisense primer 50 -GACCACAAG-
GAGGGCGATGC (complementary to a sequence encoding part of the
transmembrane domain) (Fig 1). As a control (not shown), b2-microglobulin
cDNA was ampli¢ed using the sense primer 50 -CATCCAGCGTACTC-
CAAAGA-30 and the antisense primer 50 -GACAAGTCTGAATGCTC-
CAC-30 to generate a 165-bp product. PCR was performed on 250 ng
template cDNA using the QiagenTaq PCR kit (Qiagen) according to the
manufacturer’s instructions. Reactions were done in a Minicycler (Biozym,
the Netherlands) with an initial denaturation at 941C for 3 min, 35 cycles
of 941C for 50 s (denaturation), 611C for 50 s (annealing), and 721C for 1
min (elongation), followed by a ¢nal extension at 721C for 10 min. For
cloning of the HRG ampli¢cation products, the HRG sense and antisense
primers were extended at the 50 end with GCCGGATCCG, creating a
BamHI restriction site, and with TCCGAATTC, creating a EcoRI
restriction site, respectively. The resulting ampli¢cation products were
either separated by agarose gel electrophoresis, followed by gel extraction
using Qiagen gel extraction kit (Qiagen), or used directly for digestion
with BamHI and EcoRI restriction enzymes (Roche Diagnostics,
Germany). Digested products were ligated into dephosphorylated BamHI/
EcoRI-digested pIRES2-EGFP vector (Clontech, Palo Alto, CA). After
transformation of competent DH5a bacteria with the ligated product, the
kanamycin-resistant clones were screened by PCR using primers com-
plementary to sequences of the pIRES2-EGFP vector surrounding the
insert. This resulted in PCR products of di¡erent lengths, corresponding
to di¡erent HRG isoforms, which were subjected to sequencing (Applied
Biosystems, Foster City, CA). The sequence of the a4-isoform was
submitted to GenBank (Accession Number AY207002).
Scattering assay MCF-7 cells were seeded until small islands were
formed. The cells were washed three times with PBS and were serum-
starved overnight. The following day, the cells were washed again three
times with PBS, after which the treatments (all in serum-free medium)
were applied for 2 h. Pictures were taken with an Axiovert 200M
microscope (Carl Zeiss Vision, Germany) on living cultures or after the
cultures had been ¢xed with crystal violet (0.5% in 4% formaldehyde,
30% ethanol and 0.17% NaCl) for 15 min.
Cell proliferation assays A total of 12,500 melanocytes were seeded in
the wells of a 96-well plate in 100 mL of Dulbecco’s modi¢ed Eagle’s
medium/Ham’s F12 medium containing 10% fetal bovine serum. After
attachment, 100 mL of medium, supplemented with growth factors as
indicated, was added. After 5 days, metabolic activity was measured with
a colorimetric assay. Brie£y, 100 mL of medium was taken o¡, followed by
the addition of 20 mL of 5 mg per mL 3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma) in PBS. After a 2-h incubation and
removal of all £uid, the colored formazan formed was dissolved in 100 mL
of dimethyl sulfoxide and absorption was measured with an ELISA reader
at 490 nm. Proliferation of melanoma and MCF-7 cells was measured with
the sulforhodamine B colorimetric assay. A total of 5000 cells were seeded
in 96-well plates, allowed to attach, and treated as indicated. After 5 days,
50 mL of 50% trichloroacetic acid was added to the culture medium,
followed by an incubation of 1 h at 41C. The wells were rinsed with
water, dried, incubated with 100 mL of sulforhodamine B (0.4% in 1%
acetic acid) for 30 min, rinsed with 1% glacial acetic acid, and dried
again. Bound dye was dissolved in 200 mL of 10 mM Tris bu¡er, pH 10.5,
and absorption was measured with an ELISA reader at 490 nm.
Annexin V staining Melanocytes were seeded on a collagen type I
gel for 4 days. After taking photographs, adherent cells were detached
with a swab and brought together with £oating cells. Annexin V staining
was performed with Annexin V^PE (Becton Dickinson Biosciences,
Mountain View, CA), according to the manufacturer’s instructions.
The cells were analyzed on a FACSCalibur £ow cytometer (Becton
Dickinson) with an argon^ion laser tuned at 488 nm and a helium^neon
diode laser at 635 nm. Forward light scattering, orthogonal scattering, and
two £uorescence signals were stored in list-mode data ¢les. Data
acquisition and analysis were done using the CellQuest software (Becton
Dickinson). Additional propidium iodide (PI) staining was performed to
rule out cells that were necrotic (AnnexinVþ and PIþ ).
Statistics Di¡erences between means were considered signi¢cant when
the p value was less than 0.01, using Student’s t test.
RESULTS
Expression of HERs in a panel of melanoma cell
lines Expression of HERs by melanocytes and melanoma cell
lines was examined by Western blotting and immunostaining
with anti-HER1, -2, -3, and -4 antibodies. Neither melanocytes
nor any of the melanoma cell lines showed expression of full-
length HER1 or HER4, compared with the respective posi-
tive controls A431 and T47D (data not shown). Nevertheless,
this does not necessarily mean that these receptors are comple-
tely absent. All melanoma cell lines, as well as melanocytes,
expressed HER2 (Fig 2). HER2 levels in melanocytes and in all
Figure 2. Analysis of HER2/HER3 expression in melanocytes and
melanoma cell lines.Whole-cell lysates were analyzed by immunoblot-
ting (I.B.) with anti-HER2 and anti-HER3 antibodies, as described under
Materials and Methods. Quanti¢cation of the resulting bands was done re-
latively to the level of HERs in MCF-7 mammary carcinoma cells, set at 1.
Open and ¢lled bars, HER2 and HER3 expression, respectively.
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melanoma cell lines were far below the level found in the
HER2-overexpressing SK-BR-3 mammary carcinoma cell line
(Press et al, 1993). Moreover, quanti¢cation showed that none of
the melanoma cell lines had HER2 levels that were more than
two times higher than that seen in MCF-7 mammary carcinoma
cells, often used as a control for normal expression (Press et al,
1993; Aguilar et al, 1999). Comparable levels of HER3 were
expressed by melanocytes and 11 of the melanoma cell lines.
Two melanoma cell lines (BLM and FM45) did not show
expression of HER3 protein (Fig 2). The absence of HER3
protein was due to a strongly reduced level of HER3 mRNA
in these cell lines, compared with the other cell lines (data not
shown).
Expression of HRG by melanoma cell lines Western
blotting, followed by immunostaining of total lysates using an
anti-HRG antibody directed against a cytoplasmic sequence
conserved in all transmembrane HRG isoforms, revealed the
presence of a7105-kDa band in Bowes melanoma, BLM, and
MJM, the ¢rst two having the stronger expression (Fig 3A,
top panel). This band was also present in the positive controls
MDA-MB-231 (although very faint) and COLO-16, previously
described to secrete HRG (Holmes et al, 1992) or HRG-like
activity (De Corte et al, 1994), respectively, and was not found in
the MCF-7-negative control (Aguilar et al, 1999; Aguilar and
Slamon, 2001). The size of this band indicates that it corresponds
to the full-length HRG precursor (Burgess et al, 1995; Aguilar and
Slamon, 2001). The 50-kDa band, also seen by others using this
antibody (Aguilar and Slamon, 2001), probably represents an
artifact, because it could also be found in the MCF-7 HRG-
negative cells. Also two other bands (at785 and 75 kDa), seen
in some melanoma cell lines, are likely due to cross-reactivity of
the antibody with other proteins. Because these bands were not
consistently found in cell lines expressing HRG mRNA, and
CM of these cells had no HRG-like activity (see below), they
are unlikely to represent cleavage products of transmembrane
HRG. The localization of the 105-kDa immunoreactive band at
the plasma membrane was con¢rmed for Bowes melanoma
cells by biotinylation (Fig 3B, lane 4) and by precipitation us-
ing heparin beads (Fig 3B, lane 3), which is consistent with
the presence of a heparin-binding motif at the extracellular
N-terminus of HRG.
RT-PCR analysis was carried out to verify the results obtained
by western blotting and to detect which isoforms were expressed
by the HRG-positive melanoma cell lines. Because alternative
splicing of the HRG-encoding gene leads to multiple isoforms,
with most variation in the EGF-like domain, primers were
chosen so that di¡erent lengths of ampli¢cation products were
obtained, depending on the isoform expressed. The sense and
antisense primers chosen were complementary to the mRNA
encoding a conserved part of the EGF-like domain and a
sequence conserved in all transmembrane isoforms, respectively
(Fig 1). RT-PCR using this primer set, with MDA-MB-231 and
COLO-16 as positive controls and MCF-7 as a negative control,
con¢rmed the results obtained by western blotting for Bowes
melanoma, BLM, and MJM cells (Fig 3A, bottom panel). In
addition, lower levels of mRNA were found in some other
melanoma cell lines, possibly resulting in HRG protein levels
that were below the detection level in western blotting.
Melanocytes had amounts of mRNA that were comparable to
those found in MJM cells. Because we initially did not detect
HRG protein in these cells (Fig 3A), we loaded more protein
and overexposed the ¢lm, which eventually resulted in the
appearance of a weak band at 7105 kDa (Fig 3C). The pattern
of PCR ampli¢cation products that was obtained from Bowes
melanoma suggested the presence of multiple isoforms. Cloning
and sequencing of these products revealed that a2, b1, and b2
isoforms were the most abundant transmembrane isoforms in
this cell line (Fig 3D). In addition, a new isoform, designated
a4, was identi¢ed. This isoform combines the sequences from
both the exon leading to the a isoforms and the exons leading to
the b1 isoform (Figs 1, 3D). Two bands (indicated with an open
circle) did not correspond to a speci¢c isoform because they were
the result from cross-annealing of PCR products coming from
b1^b2 or a2^b2 isoforms, presumably resulting in an imperfect
double strand with slower migration on agarose gel (Fig 3D).
Melanoma cells release functionally active HRG in the
culture medium Following cleavage in the juxtamembrane
Figure 3. Presence of HRG protein and mRNA in melanocytes and
melanoma cell lines. (a, top panel; c) HRG precursor expression was ana-
lyzed by immunoblotting (I.B.) of whole-cell lysates with an anti-HRG
antibody. (b) Total lysates of MCF-7 and Bowes melanoma (T), a heparin
precipitate (H), streptavidin precipitate (S), or control protein G^Sepharose
precipitates of Bowes melanoma cells or biotinylated Bowes melanoma
cells (bio) were analyzed by immunoblotting with an anti-HRG antibody.
(c) Prolonged exposure after immunoblotting of total lysates of melano-
cytes and Bowes melanoma cells reveals a weak band in the former. Aster-
isk, the band of full-length HRG at 105 kDa. (a, bottom panel) RT-PCR
analysis of HRG mRNA in the indicated cell lines using the primer panel
indicated in the legend to Fig 1. (d) The ¢rst lane depicts HRG mRNA
expression in Bowes melanoma as assessed by RT-PCR, using the primer
panel indicated in the legend to Fig 1. Lanes 2^5, PCR analyses of clones
derived from Bowes melanoma, representing the indicated HRG isoforms.
Open circle, bands corresponding to PCR products formed by cross-anneal-
ing of two related isoforms and thus considered as aspeci¢c.
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extracellular region, HRG are released into the culture medium
as 40- to 45-kDa proteins, depending on the isoform and glyco-
sylation level (Holmes et al, 1992; Lu et al, 1995a, b).Western blotting
of 50 concentrated CM, using an antibody directed against the
HRG extracellular domain, revealed the presence of a broad band
at the expected molecular weight (Fig 4A, lane 1). This band was
absent upon depletion of the concentrated CM from heparin-
binding factors (Fig 4A, lane 2).
To test whether the released HRG was functional, we veri-
¢ed whether CM from the melanoma cell lines was capable
of activating HERs in MCF-7 cells. Prominent tyrosine
phosphorylation of a 185-kDa protein was evident upon
treatment with the positive controls recombinant HRG-b1
(rHRG-b1) and COLO-16 CM and was further restricted to
CM from HRG-positive melanoma cell lines (Fig 4B). This
phosphorylation could be blocked by pretreating the MCF-7
cells for 30 min with the HER-speci¢c irreversible inhibitor
PD168393 (Fry et al, 1998) or by adding heparin to the CM (Fig
4C,D). Heparin treatment did not interfere as such with the
capability of HERs in MCF-7 cells to become activated, because
the combination with rHRG-b1 (lacking a heparin-binding
domain) still resulted in full phosphorylation of HERs in these
cells (data not shown). To quantify the phosphorylating capacity
of the Bowes melanoma CM, we made a comparison with the
phosphorylation of MCF-7 cells that had been treated with
di¡erent concentrations of rHRG-b1. As also shown by others
(Aguilar and Slamon, 2001), phosphorylation of a 185-kDa
protein could readily be detected using 0.5 ng per mL rHRG-b1
(Fig 4E). Treatment with CM of Bowes melanoma cells resulted
in a phosphorylation at 185-kDa equivalent to 75 ng per mL
(700 pM) rHRG-b1, correlating with a concentration of 7100
pM 45-kDa HRG in the CM. Also the kinetics of this
phosphorylation were similar, with phosphorylation occurring
already after 1 min of treatment, suggesting a similar mechanism
of direct receptor activation (Fig 4F).
One of the well-described biologic e¡ects of HRG is the rapid
induction of spreading/scattering of epithelial islands (Spencer et
al, 2000), which led us to test the e¡ect of the CM of the HRG-
positive melanoma cell lines in this assay. We found that a 2-h
treatment of serum-starved MCF-7 islands with melanoma cell
line CM resulted in a disruption of epithelial islands similar to
that of treatment with rHRG-b1. This scattering was blocked by
pretreating the cells for 30 min with PD168393 (Fig 5A).
Based on the fact that HRG contains an extracellular heparin-
binding domain, we performed precipitations using heparin
beads on 50 concentrated CM. Three consecutive precipi-
tations completely abolished the ability of the CM to induce
phosphorylation (Fig 5B, lane 4) or spreading/scattering of
epithelial MCF-7 islands (Fig 5C). In contrast, after
eluting the heparin-binding factors from the heparin beads,
desalting, and dilution of these factors in serum-free medium,
used for treating MCF-7 cells, the phosphorylation of a 185-kDa
band (Fig 5B, lane 3) as well as the induction of spreading/
scattering (Fig 5C) were evident. Both e¡ects could be blocked
by pretreating the cells for 30 min with PD168393 (Fig 5C,B,
lane 6).
An autocrine loop in Bowes melanoma cells leads to
constitutive HER phosphorylation, MAPK activation, and
increased growth Total lysates from di¡erent melanoma cell
lines were immunostained for tyrosine-phosphorylated proteins.
This revealed the presence of a highly phosphorylated protein at
185 kDa, possibly re£ecting activated HER2 and HER3, in
Bowes melanoma cells, but not in the other melanoma cell lines
tested (Fig 6A). This band was also found in the HRG-positive
COLO-16 cells, but not in the weaker HRG-positive MDA-
MB-231 cells. By precipitating HER2 and HER3 from Bowes
melanoma cells and staining for tyrosine phosphorylated pro-
teins, we could show constitutive phosphorylation of HER2
and HER3 (Fig 6B, middle panel). Treating the cells for 30 min
with PD168393 resulted in a complete block of this phospho-
rylation (Fig 6B, left and middle panels). This was not due to
alterations in receptor levels, as immunostaining for HER2 and
HER3 showed no di¡erences between untreated cells and cells
treated with PD168393 (Fig 6B, right panel). In line with this,
when tested in a 5-day growth assay, PD168393 gave a signi¢-
cant (po0.01) and concentration-dependent growth inhibition
of Bowes melanoma cells (Fig 6C). This e¡ect was not due to
general cytotoxicity because virtually no growth inhibition was
seen of MCF-7 cells (HER2/3-positive and HRG-negative) or
BLM cells (HER2/HRG-positive and HER3-negative).
Figure 4. Melanoma cells release receptor activating HRG in the
medium. (a) Immunoblotting (I.B.), using an anti-HRG antibody directed
against the EGF-like domain, of concentrated CM of Bowes melanoma,
before (lane 1) and after (lane 2) depletion of heparin-binding factors reveals
the presence of a 45-kDa protein only in lane 1. Full-length recombinant
HRG-b1 (rHRG-b1), produced in Escherichia coli (lane 3)migrates at 33 kDa
owing to di¡erences in glycosylation. (b^e) Analysis of tyrosine-phos-
phorylated proteins in serum-starved MCF-7 cells. (b) Cells treated for 30
min with serum-free medium (Untr), with rHRG-b1, or with CM from
the indicated cell lines. (c) Cells pretreated or not for 30 min with 2 mM
PD168393 (PD) and treated for an additional 30 min with serum-free med-
ium or CM from the indicated cell lines. (d) Cells pretreated or not for 30
min with 2 mM PD168393 (PD) and treated with serum-free medium or
with CM of Bowes melanoma to which heparin was added in the indi-
cated concentrations. (e) Quanti¢cation of tyrosine phosphorylation, in-
duced by treating MCF-7 cells with Bowes melanoma CM or by treating
these cells with increasing concentrations of rHRG-b1. The arrow indicates
that, by extrapolation, the phosphorylating capacity of Bowes melanoma
CM is equivalent to that of 7 5 ng per mL rHRG-b1. (f) MCF-7 cells
treated with 5 ng per mL rHRG-b1 or CM Bowes melanoma for the in-
dicated periods of time. Arrowheads, 7185-kDa tyrosine-phosphorylated
bands.
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Constitutive receptor activation in Bowes melanoma cells
could be inhibited not only by directly blocking its kinase
activity, but also the interference with ligand binding resulted
in this e¡ect. This was evident from the rapid, concentration-
dependent inhibition of HER phosphorylation and the con-
sequent growth inhibition seen upon treatment with heparin
(Fig 6D,E). The MAPK pathway is a major pathway implicated
in uncontrolled growth of melanomas (Govindarajan et al, 2003;
Satyamoorthy et al, 2003). Because it is also a well known
signaling pathway activated by HRG (Pinkas-Kramarski et al,
1998), we checked its activation status in Bowes melanoma cells
by western blotting using a phospho-MAPK-speci¢c antibody.
Constitutive HER phosphorylation of Bowes melanoma cells
was accompanied by a constitutively active MAPK pathway (Fig
6F, lane 1). Blocking HER phosphorylation with PD168393
rapidly led to a block of MAPK activation (Fig 6F, lanes 2,3),
showing that continuous HER activation is the main cause of
the constitutively activated MAPK pathway in these cells. The
importance of the continuous activation of this pathway for the
growth of Bowes melanoma cells was shown in experiments in
which we used PD98059, a MAPK inhibitor. Bowes melanoma
cells were particularly sensitive to this inhibitor and showed
signi¢cant growth inhibition at concentrations that did not have
any e¡ect on growth of control BLM or MCF-7 cells (Fig 6G).
In conclusion, constitutive HER activation by autocrine HRG
supports growth of Bowes melanoma cells via continuous
MAPK activation.
Exogenous HRG stimulates growth of melanoma cells and
melanocytes but does not protect melanocytes against
apoptosis Melanocytes depend for their survival in vitro
strongly upon the addition of extracellular stimuli. A prominent
growth factor promoting growth and survival of these cells is
bFGF (Halaban, 2000). To test whether HRG could have similar
e¡ects, we treated melanocytes with di¡erent concentrations of
rHRG-b1, bFGF, or the combination of both. As is evident
from Fig 7A, rHRG-b1 stimulated HER phosphorylation of
melanocytes and a variety of melanoma cell lines. rHRG-b1
concentration-dependently stimulated growth of melanocytes
and could even provide an additive stimulus over bFGF (Fig
7B). A signi¢cant growth stimulation was also seen when, e.g.,
MCF-7, MeWo, and A375 cells were treated with rHRG-b1
(data not shown). Because bFGF is also a potent antiapoptotic
factor for melanocytes (Alanko et al, 1999), we next tested
whether HRG might have a similar e¡ect. Upon seeding of
melanocytes on a collagen gel, these cells undergo apoptosis,
round up, and become annexin V-positive owing to the
exposure of phosphatidylserine at the outer surface of the cells.
This can be inhibited by adding bFGF to the medium (Alanko
et al, 1999) (Fig 7C,D). Although a small decrease in the
percentage of apoptotic cells was reproducibly seen upon treat-
ment with rHRG-b1, this e¡ect was negligible compared to the
antiapoptotic e¡ect of bFGF (Fig 7C,D). Overall, the results
from these assays show that HRG potently stimulates growth
of melanoma cells and melanocytes, but does not protect
melanocytes against collagen-induced apoptosis.
Defective HRG/HER system in various melanoma cell
lines As shown in Fig 8A, phosphorylation in Bowes mela-
noma cells was already maximal, because treatment with
Figure 5. Scattering of MCF-7
epithelial islands by rHRG-b1 and
by CM of HRG-positive cell lines.
Serum-starved MCF-7 cells pretreated
or not for 30 min with 2 mM PD168393,
followed by an additional 30-min treat-
ment and preparation of lysates (b) or
followed by additional 2-h treatments
before taking pictures of living cultures
(a) or crystal-violet-¢xed cultures (c). (b)
Antiphosphotyrosine immunoblotting
(I.B.) of whole-cell lysates of MCF-7
cells that were treated for 30 min with
serum-free medium, CM of Bowes mel-
anoma (CM Bowes), the heparin-binding
fraction from CM Bowes (eluate) or CM
Bowes depleted from heparin-binding
factors. Arrowhead,7185-kDa phosphory-
lated band. (c) Indicated conditions as in
(b). Bars, 50 mm.
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rHRG-b1 did not result in an increase of phosphorylation.
Consistent with this, no additional growth stimulation could be
seen upon treatment with rHRG-b1 (data not shown). The
observation that the HRG-positive BLM cells lack constitutive
receptor activation (Fig 6A) and cannot be activated upon
addition of rHRG-b1 (Fig 8A) is in agreement with the absence
of the HRG-receptor HER3 (Fig 2A) in these cells. The lack
of HER3 also accounts for the unresponsiveness of FM45 cells
to rHRG-b1 (Fig 8A). MJM cells seem to have a defective
HER-system as well: although HER2 and HER3 were present
(Fig 2A), treatment with rHRG-b1 led only to a minor
phosphorylation, compared with treated MCF-7 cells (Fig 8A).
This minor phosphorylation was due to a small increase in
phosphorylation of HER3, but not of HER2 (Fig 8B, lane 2).
To check whether HER2 can be activated in MJM cells, we
treated them for 10 min with pervanadate, a phosphatase
inhibitor. This led to phosphorylation of multiple proteins,
including HER2 and HER3 (Fig 8B, lane 3). Cotreatment with
rHRG-b1 and pervanadate led to an additional increase in
phosphorylation of only HER3 (Fig 8B, lane 4), compared to
treatment with pervanadate only. To verify whether mutations
in HER2 could be responsible for the lack of activation in
response to signaling from outside the cell, we sequenced all
exons of the HER2 gene. Apart from described polymorphisms
in the sequences encoding the transmembrane domain (Ile655 to
Val655) (Ehsani et al, 1993) and the C-terminal tail (Pro to Ala),
no mutations were found. Furthermore, biotinylation revealed
that full-length HER2 was present at the plasma membrane of
MJM cells (data not shown). So, despite the lack of mutations
of HER2 and its localization at the plasma membrane in MJM
cells, this receptor lacks the potential to become activated via
stimulation with ligands.
DISCUSSION
In this report, we investigated the expression and function of the
HRG/HER ligand^receptor system in 13 melanoma cell lines,
compared to normal melanocytes. HER2 and HER3 were found
to be the main members of the EGFR family expressed in these
cells. Nevertheless, these receptors were not overexpressed, which
is consistent with the analysis of both nevi and melanoma tumor
material by others (Natali et al, 1994; Korabiowska et al, 1996;
Persons et al, 2000; Fink-Puches et al, 2001). Similar amounts of
HER3 protein were present in melanocytes and in 11 of the
13 cell lines. The fact that two melanoma cell lines (BLM and
FM45) showed only low HER3 mRNA levels and even no de-
tectable HER3 protein is a ¢rst example of how the HRG/HER
system may be deregulated in melanoma (Fig 9). Loss of HER3
may imply that transformed melanocytes no longer depend on
HRG, normally provided by the surrounding keratinocytes
(Schelfhout et al, 2000), for their survival. Downregulation or loss
of other melanocytic RTK (e.g., c-Kit, protein-tyrosine kinase 4,
ephrin receptor EphA4) during melanoma progression has been
Figure 6. Correlation between constitutive HER activation in
Bowes melanoma, continuous MAPK activation, and increased
growth. (a) Whole lysates from 48-h serum-starved cell lines analyzed
by immunoblotting (I.B.) using an antiphosphotyrosine antibody. (b,d)
Immunoblotting of tyrosine-phosphorylated proteins in serum-starved
Bowes melanoma cells, treated or not with 2 mM PD168393 for 30 min
(b) or with di¡erent concentrations of heparin for 10 min before making
cell lysates (d). (b) The left panel indicates whole-cell lysates. Middle and right
panels, equal amounts of protein were immunoprecipitated (I.p.) using anti-
HER2 or anti-HER3 antibodies, before immunoblotting with anti-phos-
photyrosine, anti-HER2, or anti-HER-3 antibodies. (f) Bowes melanoma
cells treated with 1 mM PD168393 for di¡erent periods of time.Whole-cell
lysates were analyzed by immunoblotting using antiphosphotyrosine (top
panel) or antiphospho-MAPK antibodies (bottom panel). Arrowheads, 7185-
kDa phosphorylated bands. (c,e,g) Growth, relative to vehicle-treated cells,
as measured by sulforhodamine B assay. Cells were treated for 5 days with
the indicated concentrations of PD168393 (c,e) or heparin (e) or with 5 mM
PD98059 (g). Asterisks, di¡ers signi¢cantly (po0.01) from controls.
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described before (Easty and Bennett, 2000). Their loss may un-
couple the melanocytes from certain physiologic regulatory me-
chanisms or may indicate an independence from the growth
factor system involved. In the latter case, other systems (auto-
crine/paracrine) and/or activating mutations of other (intracellu-
lar) proteins may have substituted for the loss. In this context, it
is noteworthy that we found a mutated N-ras allele in BLM, and
also in MJM cells (see further), resulting in a constitutively active
N-ras (data not shown), whereas FM45 cells have a mutation in
the tumor suppressor PTEN (Guldberg et al, 1997), resulting in
constitutive phosphoinositide 3-kinase signaling. We have evi-
dence (unpublished data) that the absence of HER3 in BLM
and FM45 cells is accompanied by the loss of microphtalmia
transcription factor M, a melanocyte-speci¢c transcription factor
necessary for melanocyte development. Interestingly, expression
of both HER3 and microphtalmia transcription factor M has
been described to be under the control of SOX-10, a transcription
factor necessary for melanocyte development, thus making this
protein a putative regulatory candidate (Verastegui et al, 2000;
Britsch et al, 2001).
The MJM cell line represents a second example of a deregu-
lated HRG/HER system in melanoma (Fig 9). Although it ex-
presses HRG, HER2, and HER3, surprisingly, it cannot use the
secreted HRG in an autocrine loop. Following treatment of
MJM cells with exogenous HRG, HER2 is not activated at all,
whereas HER3 becomes only weakly phosphorylated. The fact
that a minute phosphorylation of HER3 still occurs is surprising,
because HER3 lacks catalytic activity and needs HER2 for its
phosphorylation in the absence of other HERs. We cannot ex-
clude that HER1 or HER4, whose levels were below the detec-
tion limit of our western blotting experiments, account for this
e¡ect.We can exclude the possible (lack of) regulatory action of
heparan sulfate proteoglycans to be responsible for the impaired
response, because the used rHRG-b1 only consists of the EGF-
like domain. Also the interference by circulating soluble HER2
Figure 8. Deregulated HRG/HER system in several melanoma cell
lines. (a) Serum-starved cells, treated with rHRG-b1 or not before the
preparation of whole-cell lysates and analysis by immunoblotting (I.B.)
using an antiphosphotyrosine antibody. (b) Equal amounts of protein from
cell lysates of MJM cells that had been treated for 10 min with rHRG-b1
and/or pervanadate were subjected to immunoprecipitation (I.p.) with anti-
HER2 or anti-HER3 antibodies before immunoblotting using an anti-
phosphotyrosine antibody. Arrowhead,7185-kDa phosphorylated band.
Figure 7. Receptor-activating and growth-promoting, but no anti-
apoptotic e¡ects of exogenous HRG on melanoma cells and mela-
nocytes. (a) Immunoblotting (I.B.), using an antiphosphotyrosine
antibody, of lysates from serum-starved cells, treated or not with rHRG-
b1. Arrowhead, 7185-kDa phosphorylated band. (b) Growth, relative to
untreated cells, as measured by 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenylte-
trazolium bromide assay. Melanocytes were treated for 5 days with the
indicated concentrations of growth factors. Asterisks, di¡ers signi¢cantly (p
o 0.01) from control. (c) Phase contrast photographs of melanocytes cul-
tured on a collagen gel for 4 days with the treatments indicated. Arrows,
rounded cells in melanocyte cultures that were left untreated or were trea-
ted with rHRG-b1. These rounded cells were not found in bFGF-treated
cultures. Bar, 50 mm (d) Histogram, showing the pro¢le of annexinV posi-
tivity in melanocytes that were cultured on a collagen gel in the absence of
added growth factors (solid line) or in the presence of 5 ng per mL bFGF
(broken line) or 50 ng per mL rHRG-b1 (dotted line). The percentage of
annexinV-positive cells is indicated.
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or HER3 ectodomains (Doherty et al, 1999; Aigner et al, 2001;
Lee et al, 2001; Justman and Clinton, 2002) is unlikely, because
CM from the HRG-positive MJM cells still induced activation
of HERs in MCF-7 cells. Biotinylation experiments suggested a
transmembrane localization of HER2 in MJM cells, whereas ana-
lysis of functional sequences failed to show mutations. Neverthe-
less, sequencing did reveal two polymorphisms, one of which (Ile
toVal at position 655 in the HER2 transmembrane domain) was
predicted to favor the formation of stable HER2 homodimers
(Fleishman et al, 2002). Although it still needs to be shown
whether the proposed model also holds for HER2 activation by
heterodimerization (following ligand binding), it would mean
that HER2 in MJM cells would be more easily activated than
in, e.g., Bowes melanoma cells, which is in contrast to our ¢nd-
ings. It thus seems unlikely that this polymorphism may provide
an explanation for the observed lack of HER2 activation in MJM
cells treated with HRG. A possible role for the other polymorph-
ism we identi¢ed in MJM cells has not been established yet. Re-
maining explanations for the lack of HER2 activation following
stimulation with HRG are the interference with ligand binding
by sterical hindrance, the constitutive association or action of in-
tracellular negative regulatory proteins or receptor mislocaliza-
tion (although transmembrane).
Here, we have shown by western blotting, RT-PCR, cloning,
and using functional assays the presence and function of HRG as
new growth factors produced by human melanoma cells. In addi-
tion to three known HRG isoforms, we could identify a new iso-
form, designated a4. This isoform combines the sequences that
normally lead to either a- or b-isoforms. A similar combination
was already described for the a3-isoform, which di¡ers from the
a4 -isoform because the latter contains the coding sequence for
the transmembrane domain (Wen et al, 1994) (Fig 1). Neverthe-
less, the resulting protein is the same, because this a^b combina-
tion leads to a frameshift, resulting in the generation of a stop
codon upstream of the sequence encoding the transmembrane
domain. This truncated protein is most likely cytosolic because
the transmembrane domain functions as a signal peptide (Burgess
et al, 1995).The presence of HRG in melanomas ¢ts with the neu-
roectodermal origin of melanocytes and the fact that HRG are
molecules typically expressed in neuroectodermal tissues (March-
ionni et al, 1993; Meyer and Birchmeier, 1995). Although melano-
cytes showed HRG expression at the mRNA level, HRG could
barely be detected at the protein level, suggesting the presence of
(post)translational negative regulatory mechanisms in these cells.
Activating mutations in H-ras have been shown to result in upre-
gulation of HRG in mammary epithelial cells (Mincione et al,
1996). Although two of the HRG-producing cell lines (BLM
and MJM) have an activating mutation in N-ras, transient trans-
fections using dominant-negative and constitutively active N-ras
constructs learned that this was unlikely to be the underlying
cause of the increased HRG expression (data not shown). Thus,
the molecular basis for the high HRG expression in some mela-
noma cell lines is not clear, yet. Although exogenous HRG did
not exert a signi¢cant antiapoptotic e¡ect, it potently stimulated
growth of cultured melanocytes and melanoma cells and could
even provide an additive growth stimulation over bFGF. Upregu-
lation of HRG expression in melanomas may result in the gen-
eration of an autocrine loop and in the independence from HRG
normally provided by the keratinocytes (Schelfhout et al, 2000).
This decreased dependence from paracrine growth factors is one
of the hallmarks of melanoma progression (LaŁ zaŁ r-MolnaŁ r et al,
2000). Our data clearly show that in the Bowes melanoma cell
line, in the absence of receptor overexpression, HER2 and
HER3 are permanently activated, leading to continuous MAPK
activation and stimulation of growth. This activation is due to
continuous ligand^receptor interactions and not to, e.g., activat-
ing mutations. Arguments hereto are that the phosphorylation
could be abolished by adding heparin to the culture medium
and that refreshing of the culture medium led to a transient, gra-
dual decrease in receptor phosphorylation, followed by a gradual
recovery to the initial levels (data not shown). Thus, the Bowes
melanoma cell line, with its autocrine loop, represents a third ex-
ample of how the HRG/HER system may be deregulated in
melanoma (Fig 9). Expression of the HRG/HER systemwas also
described in various other types of cancers (e.g., breast, lung, en-
dometrium, thyroid, head and neck, colon, ovarium) (Ethier et al,
1996; Fernandes et al, 1999; Srinivasan et al, 1999; Fluge et al, 2000;
O-Charoenrat et al, 2000; Gilmour et al, 2002;Venkateswarlu et al,
2002). Although in only some of these studies constitutive recep-
tor activation, owing to an autocrine loop, was looked at, it may
play a role in the other cases as well, rendering it a possible target
for future therapies. In line with this is the increased attention
that is being given toward receptor activation status in certain
cancers, rather than only taking into account receptor levels as a
criterium of malignancy (Thor et al, 2000).
Overall, it is striking that two of the three HRG-positive cell
lines, BLM and MJM, cannot use the secreted HRG in an auto-
crine loop, because of the absence of HER3 or because of an im-
paired HER2 activation, respectively. Still, in a physiologic
situation, the HRG secreted by such cells may have prominent
e¡ects on the surrounding cells, directly or indirectly contribut-
ing to malignant progression. Direct e¡ects may include an in-
creased motility of the surrounding keratinocytes (Schelfhout et
al, 2002), possibly rendering the environment in which the mela-
nocytes reside less tight. Indirect e¡ects may be the stimulation of
angiogenesis owing to a HRG-mediated upregulation of vascular
endothelial growth factor or increased expression of other
growth factors by the target cells (O-Charoenrat et al, 2000;
Talukder et al, 2000;Yen et al, 2000; Ruiter et al, 2002).
Figure 9. Schematic representation of the several deregulations of
the HRG/HER system found in human melanoma cells. In melano-
cytes and the majority of melanoma cell lines, HERs can be activated by
exogenous HRG. The absence of HER3 in BLM and FM45 cells or the
presence of functionally inactive HER2 in MJM hampers HRG respon-
siveness. Bowes melanoma cells show constitutive HER activation, owing
to the presence of an autocrine loop.
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In summary, we have shown the presence of HRG, including
one new isoform, as new factors produced and secreted by hu-
man melanoma cell lines. The HRG/HER system is functional
in melanocytes and in the majority of melanoma cell lines, lead-
ing to growth stimulation. Nevertheless, multiple deregulations
in this growth factor system may release the melanocytes from
their natural dependence on keratinocyte-derived factors and thus
represent a step toward melanoma progression. Lack of stimula-
tion by HRG in some melanoma cell lines is due to the loss of
expression of HER3 protein or to a severely impaired HER2 ac-
tivation. In contrast, the aberrant expression and secretion of
HRG by melanoma cells may serve as an autocrine and/or para-
crine signal, promoting cell growth and/or migration. These dis-
tinct types of deregulation of the HRG/HER system may
contribute to the malignant phenotype of melanoma cells. In
the future, it will be important to verify whether these deregula-
tions are present in tumor samples of melanoma patients and may
become a therapeutic target for this disease with ever increasing
incidence.
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